|
US6472147B1
(en)
*
|
1999-05-25 |
2002-10-29 |
The Scripps Research Institute |
Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
|
|
US7037706B1
(en)
|
1999-09-29 |
2006-05-02 |
Xenoport, Inc. |
Compounds displayed on replicable genetic packages and methods of using same
|
|
WO2001023619A1
(en)
|
1999-09-29 |
2001-04-05 |
Xenoport, Inc. |
Compounds displayed on replicable genetic packages and methods of using same
|
|
US8288322B2
(en)
*
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
|
CA2798625C
(en)
*
|
2000-04-17 |
2017-01-24 |
Dyax Corp. |
Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
|
|
WO2002061071A2
(en)
*
|
2000-12-18 |
2002-08-08 |
Dyax Corp. |
Focused libraries of genetic packages
|
|
EP1385984A4
(en)
*
|
2001-03-21 |
2007-06-13 |
Xenoport Inc |
COMPOUND PRESENTED ON AN ICOSAEDRIC PHAGE AND METHOD OF USE THEREOF
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
US7202045B2
(en)
*
|
2001-09-19 |
2007-04-10 |
Regents Of The University Of Michigan |
Detection and treatment of cancers of the lung
|
|
US7175983B2
(en)
*
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
|
CA2505849C
(en)
*
|
2002-07-30 |
2013-11-05 |
Morphosys Ip Gmbh |
Novel tricistronic vectors and uses therefor
|
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
PT1558643E
(pt)
|
2002-11-09 |
2009-08-24 |
Immunocore Ltd |
Apresentação de um receptor das células t
|
|
DK1587907T3
(da)
|
2003-01-07 |
2011-04-04 |
Dyax Corp |
Kunitz-domænebibliotek
|
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
KR20140066259A
(ko)
|
2004-02-06 |
2014-05-30 |
모르포시스 아게 |
항-ｃｄ３８ 인간 항체 및 그의 용도
|
|
AU2005235811B2
(en)
|
2004-02-06 |
2011-11-03 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
|
WO2006095345A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Ramot At Tel-Aviv University Ltd. |
Targeted drug-carrying bacteriophages
|
|
RU2447085C2
(ru)
|
2005-05-18 |
2012-04-10 |
МорфоСис АГ |
Анти-gm-csf антитела и их применение
|
|
US8114964B2
(en)
|
2005-05-19 |
2012-02-14 |
Centocor, Inc. |
Anti-MCP-1 antibodies, compositions, methods and uses
|
|
TW200745162A
(en)
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
|
CA2625681C
(en)
|
2005-10-12 |
2016-08-02 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
|
|
ATE463512T1
(de)
|
2005-11-09 |
2010-04-15 |
Morphosys Ag |
Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
|
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
|
AU2006350452B2
(en)
*
|
2005-12-20 |
2012-10-25 |
Morphosys Ag |
Novel collection of HCDR3 regions and uses therefor
|
|
US8101727B2
(en)
|
2006-03-30 |
2012-01-24 |
Novartis Ag |
Compositions and methods of use for antibodies of c-Met
|
|
EP2021795A4
(en)
|
2006-05-04 |
2009-05-13 |
Abmaxis Inc |
CROSS SPECIES AND MULTI-SPECIAL PRESENTATION SYSTEMS
|
|
SG175602A1
(en)
|
2006-07-05 |
2011-11-28 |
Catalyst Biosciences Inc |
Protease screening methods and proteases identified thereby
|
|
ES2348343T3
(es)
|
2006-12-12 |
2010-12-03 |
Morphosys Ag |
Internalización.
|
|
US9062097B2
(en)
*
|
2007-08-21 |
2015-06-23 |
Morpho Sys AG |
Methods for the formation of disulphide bonds
|
|
BRPI0816094A2
(pt)
|
2007-08-30 |
2015-03-03 |
Daiichi Sankyo Co Ltd |
Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
EP3124497B1
(en)
|
2007-09-14 |
2020-04-15 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US12529164B2
(en)
|
2007-09-14 |
2026-01-20 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
MX2010005603A
(es)
|
2007-11-26 |
2010-08-02 |
Bayer Schering Pharma Ag |
Anticuerpos antimesotelina y usos de los mismos.
|
|
EP2653545A1
(en)
*
|
2008-02-05 |
2013-10-23 |
Bicycle Therapeutics Limited |
Methods and compositions
|
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
|
JP5667043B2
(ja)
|
2008-04-15 |
2015-02-12 |
アメリカ合衆国ＧＯＶＥＲＮＭＥＮＴ ＯＦ ＴＨＥ ＵＮＩＴＥＤ ＳＴＡＴＥＳ ＯＦ ＡＭＥＲＩＣＡ， ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ＴＨＥ ＳＥＣＲＥＴＡＲＹ， ＤＥＰＡＲＴＭＥＮＴ ＯＦ ＨＥＡＬＴＨＡＮＤ ＨＵＭＡＮ ＳＥＲＶＩＣＥＳ |
阻害性オリゴヌクレオチドを送達するための組成物および方法
|
|
US10485879B2
(en)
|
2008-04-15 |
2019-11-26 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
|
|
JP5780951B2
(ja)
|
2008-04-24 |
2015-09-16 |
ダイアックス コーポレーション |
新規のｈｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計、ならびに新規のｌｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計を含む、遺伝子パッケージのライブラリ
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
WO2010028347A2
(en)
|
2008-09-05 |
2010-03-11 |
President & Fellows Of Harvard College |
Continuous directed evolution of proteins and nucleic acids
|
|
WO2010079189A1
(en)
|
2009-01-09 |
2010-07-15 |
Morphosys Ag |
Display vectors and methods and uses thereof
|
|
TWI480050B
(zh)
|
2009-02-10 |
2015-04-11 |
Daiichi Sankyo Co Ltd |
抗－ｍｓｔ１ｒ抗體及其用途
|
|
JP2012524524A
(ja)
|
2009-04-27 |
2012-10-18 |
ノバルティス アーゲー |
ＩＬ−１２レセプターβ１サブユニットに特異的な治療用抗体の組成物および使用方法
|
|
PE20120532A1
(es)
|
2009-04-27 |
2012-05-18 |
Novartis Ag |
ANTICUERPOS ANTI-ActRIIB
|
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
NZ596058A
(en)
*
|
2009-04-30 |
2013-08-30 |
Cytos Biotechnology Ag |
Influenza hemagglutinin compositions and uses thereof
|
|
CA2758356C
(en)
|
2009-05-29 |
2016-07-26 |
Morphosys Ag |
A collection of vh and vl pairs having favourable biophysical properties and methods for its use
|
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
|
AU2010291902A1
(en)
*
|
2009-09-14 |
2012-04-05 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
|
WO2011062862A1
(en)
|
2009-11-17 |
2011-05-26 |
Centocor Ortho Biotech Inc. |
Improved bacterial membrane protein secrection
|
|
ES2581571T3
(es)
|
2009-11-17 |
2016-09-06 |
Janssen Biotech, Inc. |
Presentación de proteínas diméricas de disulfuro vinculado en fagos filamentosos
|
|
ES2551871T3
(es)
|
2010-01-29 |
2015-11-24 |
Morphosys Ag |
Genotecas combinatorias de anticuerpos de roedor
|
|
EP2566892B1
(en)
|
2010-05-06 |
2017-12-20 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
|
PH12012502193A1
(en)
|
2010-05-06 |
2021-08-09 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
KR102318383B1
(ko)
|
2010-07-16 |
2021-10-27 |
아디맵 엘엘씨 |
항체 라이브러리
|
|
AU2011290672B2
(en)
|
2010-08-20 |
2015-07-09 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
MX2013003828A
(es)
|
2010-10-05 |
2013-06-28 |
Daiichi Sankyo Co Ltd |
Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
|
|
US8367586B2
(en)
|
2010-11-19 |
2013-02-05 |
Morphosys Ag |
Collection and methods for its use
|
|
CA2825370A1
(en)
|
2010-12-22 |
2012-06-28 |
President And Fellows Of Harvard College |
Continuous directed evolution
|
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
|
ME03073B
(me)
|
2011-10-19 |
2019-01-20 |
Galapagos Nv |
Ant agonisti il17с za lečenje zapaljenskih poremećaja
|
|
CN104105709A
(zh)
|
2011-12-05 |
2014-10-15 |
诺华股份有限公司 |
抗her3的结构域ii的表皮生长因子受体3(her3)抗体
|
|
EP3590538A1
(en)
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
JP2015508638A
(ja)
|
2012-02-03 |
2015-03-23 |
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ |
ファージディスプレイを用いてペプチド誘導体ライブラリーを定量化するための方法
|
|
IN2014KN02831A
(https=)
|
2012-05-24 |
2015-05-08 |
Mountgate Group Ltd |
|
|
KR102410763B1
(ko)
|
2012-08-17 |
2022-06-20 |
모르포시스 아게 |
복합체-특이적 항체 및 항체 단편 및 그의 용도
|
|
US9376489B2
(en)
|
2012-09-07 |
2016-06-28 |
Novartis Ag |
IL-18 binding molecules
|
|
CA2890483A1
(en)
|
2012-11-09 |
2014-05-15 |
Robert ARCH |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
|
|
WO2014096333A1
(en)
|
2012-12-20 |
2014-06-26 |
Morphosys Ag |
Anti-staphylococcal antibodies
|
|
EP3611189A1
(en)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antibodies against notch 3
|
|
ES2701051T3
(es)
|
2013-03-15 |
2019-02-20 |
Novartis Ag |
Conjugados de anticuerpo-fármaco
|
|
EA031471B1
(ru)
|
2013-04-12 |
2019-01-31 |
МорфоСис АГ |
Антитела, направленные на m-csf
|
|
EP2986642A1
(en)
|
2013-04-17 |
2016-02-24 |
MorphoSys AG |
Antibodies targeting specifically human cxcr2
|
|
NZ759969A
(en)
|
2013-12-20 |
2022-12-23 |
Fred Hutchinson Cancer Center |
Tagged chimeric effector molecules and receptors thereof
|
|
WO2015134121A2
(en)
|
2014-01-20 |
2015-09-11 |
President And Fellows Of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
|
NZ724320A
(en)
|
2014-03-14 |
2022-05-27 |
Adaptimmune Ltd |
Tcr libraries
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
WO2016077052A2
(en)
|
2014-10-22 |
2016-05-19 |
President And Fellows Of Harvard College |
Evolution of proteases
|
|
TW201625692A
(zh)
|
2014-11-14 |
2016-07-16 |
諾華公司 |
抗體藥物結合物
|
|
WO2016160618A2
(en)
|
2015-03-27 |
2016-10-06 |
University Of Southern California |
Car t-cell therapy directed to lhr for the treatment of solid tumors
|
|
WO2016168631A1
(en)
|
2015-04-17 |
2016-10-20 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
EP3288569A4
(en)
*
|
2015-04-29 |
2018-12-19 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
EP3095465A1
(en)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Combination of fgfr4-inhibitor and bile acid sequestrant
|
|
WO2016197064A1
(en)
|
2015-06-04 |
2016-12-08 |
Epstein Alan L |
Lym-1 and lym-2 targeted car cell immunotherapy
|
|
EP3303387A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
|
UY36751A
(es)
|
2015-06-26 |
2017-01-31 |
Novartis Ag |
Anticuerpos de factor xi y métodos de uso
|
|
WO2017015545A1
(en)
|
2015-07-22 |
2017-01-26 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
|
US11524983B2
(en)
|
2015-07-23 |
2022-12-13 |
President And Fellows Of Harvard College |
Evolution of Bt toxins
|
|
WO2017019895A1
(en)
|
2015-07-30 |
2017-02-02 |
President And Fellows Of Harvard College |
Evolution of talens
|
|
EA038332B1
(ru)
|
2015-09-09 |
2021-08-10 |
Новартис Аг |
Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
|
|
HRP20210650T1
(hr)
|
2015-09-09 |
2021-05-28 |
Novartis Ag |
Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
|
|
GB201516270D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516274D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516272D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516275D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516277D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR libraries
|
|
GB201516269D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
GB201516265D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
EP3569244A1
(en)
|
2015-09-23 |
2019-11-20 |
CytoImmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
|
IL310721B2
(en)
|
2015-10-23 |
2025-11-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
AU2017219254B2
(en)
|
2016-02-17 |
2019-12-12 |
Novartis Ag |
TGFbeta 2 antibodies
|
|
HRP20211059T1
(hr)
|
2016-02-19 |
2021-10-01 |
Morphosys Ag |
Antitijela za il-17c
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
WO2018087349A1
(en)
|
2016-11-14 |
2018-05-17 |
Morphosys Ag |
Fab molecules with a rodent hinge region and a non-rodent ch1 region
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
US11447809B2
(en)
|
2017-07-06 |
2022-09-20 |
President And Fellows Of Harvard College |
Evolution of tRNA synthetases
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
US12060553B2
(en)
|
2017-08-25 |
2024-08-13 |
President And Fellows Of Harvard College |
Evolution of BoNT peptidases
|
|
WO2019056002A1
(en)
|
2017-09-18 |
2019-03-21 |
President And Fellows Of Harvard College |
CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
|
|
EP3706795A4
(en)
|
2017-11-09 |
2021-10-13 |
Pinteon Therapeutics Inc. |
METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
|
|
EP3713965A1
(en)
|
2017-11-22 |
2020-09-30 |
Novartis AG |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
|
CN119930831A
(zh)
|
2018-03-14 |
2025-05-06 |
纪念斯隆凯特琳癌症中心 |
抗聚唾液酸抗体及其用途
|
|
EP3774926A1
(en)
|
2018-04-05 |
2021-02-17 |
Bio-Rad ABD Serotec GmbH |
Display systems for proteins of interest
|
|
AU2019270342A1
(en)
|
2018-05-16 |
2020-10-29 |
Morphosys Ag |
Antibodies targeting glycoprotein VI
|
|
WO2019241649A1
(en)
|
2018-06-14 |
2019-12-19 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
|
SG11202100721SA
(en)
|
2018-07-23 |
2021-02-25 |
Univ Alberta |
Genetically-encoded bicyclic peptide libraries
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
EP3938400B1
(en)
|
2019-03-11 |
2025-07-30 |
Memorial Sloan Kettering Cancer Center |
Cd22 antibodies and methods of using the same
|
|
JP7617012B2
(ja)
|
2019-03-14 |
2025-01-17 |
モルフォシス・アーゲー |
Ｃ５ａＲを標的とする抗体
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
TW202216761A
(zh)
|
2020-07-16 |
2022-05-01 |
瑞士商諾華公司 |
抗β細胞素抗體、其片段及多特異性結合分子
|
|
US20230357398A1
(en)
|
2020-09-24 |
2023-11-09 |
Morphosys Ag |
Novel human antibodies binding to human cd3 epsilon
|
|
MX2023008285A
(es)
|
2021-01-13 |
2023-09-12 |
Memorial Sloan Kettering Cancer Center |
Conjugado de anticuerpo anti-dll3-farmaco.
|
|
CA3204628A1
(en)
|
2021-01-13 |
2022-07-21 |
John T. POIRIER |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
JPWO2023032955A1
(https=)
|
2021-08-31 |
2023-03-09 |
|
|
|
WO2023180346A1
(en)
|
2022-03-22 |
2023-09-28 |
Morphosys Ag |
Deimmunized antibodies specific for cd3
|
|
GB202204159D0
(en)
|
2022-03-24 |
2022-05-11 |
Heptares Therapeutics Ltd |
Antibodies
|
|
WO2024236163A1
(en)
|
2023-05-17 |
2024-11-21 |
Morphosys Ag |
T cell receptor beta constant region 2 (trbc2) antibodies
|
|
WO2025003511A1
(en)
|
2023-06-30 |
2025-01-02 |
Morphosys Ag |
Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|